A NEW SEGREGANT SERIES OF HUMAN B CELl, ALI.OANTIGENS series of B cell alloantigens. Allogeneic mixed lymphocyte responses have been exploited to identify five new histocompatibility antigens. These determinants, which we have designated secondary B cell (SB) antigens, are distinct from the DR antigens; however, both the SB and the DR antigens are encoded in the same region of the MHC, both are preferentially expressed on B cells, and both stimulate secondary allogeneic proliferative and cytotoxic responses. These data are consistent with the interpretation that the SB antigens and DR antigens are products of duplicated ancestral genes.
Materials and Methods
Human Reagents. Human peripheral blood mononuclear cells were obtained by batch leukapheresis, separated by flotation on Ficoll (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) -Hypaque (Winthrop Laboratories, New York), and cryopreserved as previously described (15) . Plasma from five or more normal males was pooled, frozen in aliquots at -20°C, and used as a normal plasma pool. Serotyping and HLA-D typing were performed by standard procedures (16) .
Lymphocyte Priming. Responder and stimulator cells were thawed, washed, and resuspended in RPMI-1640 medium with glutamine (Grand Island Biological Co., Grand Island, N. Y.) that was supplemented with penicillin (10 U/ml) and streptomycin (10 #g/ml) (complete medium). 6 X 106 responding cells were mixed with 3 x 106 irradiated (2,000 rad; cesium source) stimulator cells in a 25-cm 2 tissue culture flask in 8 ml ofcomplete medium supplemented with 0.5 ml of normal human plasma. The flask was incubated upright in 5(~ CO2-95% air at 37°C for 10 d. Primed cells were either used fresh or after cryopreservation. Cell-mediated Cytotoxicity. 3 × 106 primed cells were cocultured with 10 X l0 s irradiated stimulator cells in 6 ml of complete media with 15% heat-inactivated human plasma in 25-cm 2 tissue culture flasks for 5 d. The target cells and blocking cells used were either: (a) lymphoblastoid B cell lines that had been transformed with Epstein-Barr virus (17) , or (b) peripheral. blood mononuclear cells that had been precultured for 3 d in complete medium with 1:200 dilution of phytohemagglutinin (PHA) (M form; Grand Island Biological Co.)--these cells were generally >90% T cells by analysis of E-rosette binding, surface immunoglobulin, and esterase staining and are therefore referred to as T lymphoblasts. Targets were labeled by a 90-min incubation with Na[SXCr]O4 (New England Nuclear, Boston, Mass.). Cytotoxicity was determined in a standard 6-h chromium-release assay (15) using 1 × 104 target cells and effector:target ratios of 20:1 and 7:1. For cold-target-cell inhibition assays, effector cells and unlabeled blocking cells were preincubated for 10 min before the addition of the labeled targets; the effector:target cell ratio used was 20:1 and the blocker:target cell ratios were 60:1 and 20:1.
Primed-Lymphocyte Typing (PLT)
Data Analysis. Proliferative data were calculated as the geometric mean and standard error.
Data were expressed as percent relative response. For primary proliferative responses, the percent relative response was calculated as [(counts per minute for experimental)/(counts per minute for a pool of 10 allogeneic cells)[ X 100. For secondary proliferation, the percent relative response was calculated as [(counts per minute for unknown restimulating cell)/(counts per minute for the specific restimulating cell)] X 100. The geometric SE for this ratio was <1.2 for all data shown. For cytotoxic assays, percent specific lysis was calculated as [(counts per minute experimental) -(counts per minute media)]/[(eounts per minute detergent) -(counts per minute media)]. Spontaneous release was always < 18% for B cells and <27% for T lymphoblasts. The arithmetic SE for percent specific release never exceeded 5%. To assure objectivity in scoring positives and negatives in proliferative and cytotoxic assays, assignment was made by cluster analysis (18) . This analysis tests all possible assignments of donors as positive and 
Results
In order to use cellular responses to define new histocompatibility antigens, responder lymphocytes were primed in vitro with stimulator cells with which they were matched for all known HLA antigens (A, B, C, D, DR, and MB). Table I Table II ). Despite the absence of strong proliferation during priming, many of the primed lymphocyte reagents showed strong specific restimulation (i.e., by the original stimulating, but not responding, cell). In fact, many of the primed cells were highly discriminatory reagents with a bimodal distribution of positive and negative responses, suggesting that they recognized predominantly a single antigen (or a cluster of highly associated antigens). Analysis of the responses revealed that the specificity of all 22 reagents tested (in a total of 308 different responder-stimulator combinations) could be explained in terms of recognition of five distinct antigens (either singly or in pairs). Table II illustrates that at least two different reagents could be identified which defined each of the five antigens, designated SB1 through SB5. Four lymphocyte populations that had been primed to DRw antigens were included as controls in this experiment. Assignment of positive and negative was made on the basis of cluster analysis to achieve objectivity in the scoring of results. However, the results were sufficiently clear that inspection would have been almost as effective in making assignments; in the experiment shown, 65 out of 67 of the positive assignments were made in combinations with relative responses ~60%, and 126 out of 129 of the negative assignments were in combinations with relative responses ~40%.
Each SB antigen was identified with two different PLT reagents; there was concordance between the results with the two different reagents in 69 out of the 70 pairs of SB typing results. 8 of the 14 donors could be unequivocally assigned two specificities; 6 of the 14 were assigned only one specificity. Furthermore, the results were internally consistent in that the specificity of the primed lymphocytes could be predicted on the basis of the SB antigen assignment of the original responder and stimulator cells (e.g., S 11 anti-H9 is an SB2,5 anti-SB 1,2; and, as predicted, recognizes only SB 1).
Our results confirmed the reports of others (20) (21) (22) ) that DR antigens (or antigens very highly associated with them) can induce stimulation in secondary proliferative responses. The data in this experiment and others (data not shown) suggest that the single apparent disparity between serotyping and PLT (donor F2) reflects difficulty in scoring positives and negatives in PLT rather than a difference between the antigens recognized in PLT and those recognized serologically. Results with D/DRdiscordant donors like R5 support the conclusion that the DR antigen itself can stimulate strong secondary proliferation.
Comparison of the assignments of SB antigens and DR antigens for each donor reveals that there is no consistent relationship between a donor's HLA-DR antigens and his SB antigens. The SB antigens are clearly not subsets (or splits) of the known D-region antigens, because it is impossible to make a consistent assignment of SB antigens as subgroups of Dw, DRw, or MB alleles. Furthermore, the finding that none of the five donors matched for A 1,2,B7,8, and Dw/DRw2,3 are also identical for SB suggest that there may not even be a very strong linkage disequilibrium between HLA-DR and SB antigens.
The mean proliferative response for specific restimulation for the SB reagents was 16,900 cpm compared with a mean response of 15,900 cpm for the DR reagents. Thus, both series of antigens can induce a strong secondary proliferative response. It is noteworthy that when lymphocytes are primed concurrently to SB and DR, there often is a strong preferential response to the DR specificity, as illustrated by the DRw4-directed PLT (Table II) HLA-linkage Studies. To determine whether the SB antigens are coded by HLAlinked genes, segregation analysis was performed in seven families, and the results were consistent with HLA linkage in all families. Evidence That SB Antigens Are Target Antigens for Cell-mediated Cytotoxicity (CML ). We analyzed these antigens to determine if they can be recognized as target antigens in CML, using principally the same donors as in the proliferative studies. Cytotoxic activity was assayed in secondary responses on target cells from Epstein-Barr virustransformed lymphoblastoid cell lines (Table IV) . As controls, cytotoxic effector cells were also generated against DR differences. Assignment of positive and negative was made on the basis of cluster analysis, although the results were sufficiently clear that inspection would have been almost as effective in making assignments. Cytotoxicity was generated in the same combinations of responder and stimulators that had generated SB-specific proliferation--i.e., those matched for HLA-A, -B, -C, -D, -DR, and MB. Killing by these effector cells differed among target cells that were identical for HLA-A, -B, -C, -D, -DR, and MB. The distribution of the CML antigens among the donors was similar to the distribution of the antigens defined by proliferation. Assignment of antigens by cytotoxic assay agreed with that by PLT in 58 out of 60 comparisons. If the two examples of apparent discordance between CML and PLT (Table IV, footnote :~) were consistent, that would suggest that the two assays detected different antigens; instead, the discordances were limited to the SB4 antigen (which is hardest to define) and were not confirmed by other experiments (Table IV; and S. Shaw, A. H. Johnson, and G. M. Shearer. Unpublished observations.).
There was a perfect correlation (24 out of 24) between the DR assignment of cells and their susceptibility to lysis by effector cells generated by DRw2-specific priming and DRw3-specific priming. This confirms previous reports (23-25) that HLA-DR antigens per se (or antigens highly associated with them) can be target antigens for allogeneic CML. Again, results relating to the D/DR-discordant donor R5 indicated that the DR antigen itself (in the absence of the concordant D specificity) might function as the cytotoxic target antigen.
Another feature of the cytotoxicity results is that the SB-specific killing is not restricted either by HLA-A, -B, and -C or by HLA-DR. This is evident in the typing for SB1 by CML reagents derived from two completely independent responder and stimulator cell combinations. The first five targets share all previously defined HLA antigens with the stimulator cell in the first combination (donor H9) but none of them with the stimulator cell in the second combination (donor FB6). The magnitude of the killing by these effector cells and their specificity are equivalent; therefore matching for A, B, C, D, DR, and MB is not necessary for SB-specific killing.
To estimate the expression of SB antigens on B cells relative to that on T cells, cytotoxicity was compared on B lymphoblastoid cell lines and on PHA-stimulated lymphoblasts (Table IV) . Both DR-specific and SB-specific CML effeetor cells preferentially lysed the appropriate B cell lines. The low level of lysis of the T iymphoblasts by effectors of both specificities could be explained by the expression of Ia antigens on a small fraction of lymphoblasts 3 d after stimulation with PHA (26, 27) or by limited contamination of the mitogen-stimulated cells with B cells and macrophages. The poor lysis of the T lymphoblasts is not a result of their being insusceptible to lysis, because they were well lysed by control effector cells specific for HLA-A and -B antigens (data not shown). Confirmation that the SB antigens are B cell antigens is provided by studies showing that the SB-specific CML is inhibited by a monoclonal antiserum specific for an Ia-like molecule (S. Shaw and L. Lampson.
Manuscript in preparation.).
Cold-Target Blocking Studies Confirm That Effectors Can Be Generated against Both DR and SB. CML effector cells were generated against individual DR or SB antigens and assayed on B cells of the stimulator cell donor. In a typical experiment (Table V) , each such effector:target combination was assayed both unblocked and in the presence of blocking B cells from 12 donors. As in previous studies, the presence or absence of blocking was determined by cluster analysis, although inspection would have resulted in the same assignments. The results confirmed those observed in direct lysis. First, effector cells raised against DRw2 or DRw3 differences were inhibited by all blocking cells that had the appropriate DRw specificity and only by those cells. Second, effector cells raised against individual SB differences were inhibitable only by blocking cells that expressed the appropriate SB specificity (assigned by PLT); the concordance in assignment of antigen between direct killing and cold-target inhibition is complete and strengthens the evidence that the proliferation-inducing antigen and the CML antigen are either identical or in very strong linkage disequilibrium. The differences in SB-specific blocking by cells that are DR matched and vice versa confirm the independence of these two antigens.
DR-and SB-specific Killing are Both Inhibited Better by B Cell Lines Than by T Lymphoblasts.
To confirm that SB and DR antigens were similar with respect to greater expression on B cells than on T cells, B and T cells were compared in coldtarget inhibition of DR-and SB-specific CML. Lymphoblastoid B cell lines from the stimulator inhibted SB-and DR-specific lysis almost completely, but blockers from the responder donor did not (Table VI) . In contrast, PHA lymphoblasts from the stimulator donor blocked poorly, only a little better than did cells from the responder donor.
Analysis of SB-specific Killing in an HLA-Recombinant Family. SB-specific killing was analyzed in an unusual HLA-recombinant family, in which we first identified SBI and SB4 in secondary proliferative responses (19) . CML effector cells raised against SB 1 and SB4 among donors of phenotype A 1,2,B7,8 were assayed on lymphoblastoid B cell lines from five family members and from three control donors (Table VII ). The data demonstrate two findings. First, the target antigens for CML, like the SBproliferative antigens in this family (19) , segregate with HLA-A and -B markers, except in the recombinant donor. SB1 segregates with the a haplotype, and SB4 segregates with the b and d haplotype; the recombinant, who has inherited the HLA-A and -B antigens from the b haplotype, has inherited the SB antigen from the a haplotype. Thus, the SB1 and 4 antigens map to a region of HLA outside of the HLA-A/B segment; although homozygosity for other HLA markers (C2,C4,DR,D,GLO) precludes precise mapping in this family, these cytotoxicity data First, what other investigations suggest the existence of antigens similar to those described in this study? Since the development of techniques for secondary human allogeneic responses (28) (29) (30) , it has become apparent that several different antigens stimulate secondary proliferative responses. Both D and DR antigens can independently induce secondary responses (20) (21) (22) . Family studies suggest that antigens distinct from the D and DR antigens can be recognized by PLT (for an A/B recombinant family [31] , a B/D recombinant family [32] , and a D/GLO recombinant family [33] ). In addition, several laboratories have demonstrated that priming between donors who are phenotypically identical for D/DR either in families, or between unrelated donors can result in generation of PLT reagents that appear to recognize HLA-linked antigens distinct from D and DR (22, 34, 35) .
There is no direct precedent for the antigens we have defined by cytotoxic responses. There are CML antigens distinct from the known serologically defined HLA-A, -B, and -C antigens (36) , but these have generally been found on T cell targets, and are thus probably distinct from the SB antigens (which are not well expressed on T cells). Studies of primary cytotoxic responses assayed on appropriate targets (monocytes [23] , Epstein-Barr virus-transformed B cells [24] , and mitogen-stimulated B lymphoblasts [25] ) demonstrated CML specific for B cell alloantigens, which could be largely explained by reactivity with DRw antigens. The failure to detect SB antigens in these experiments probably reflects the fact that cytotoxic responses to SB antigens are seldom seen in primary sensitization (S. Shaw, A. H. Johnson, and G. M. Shearer. Unpublished observations.) and the DR-specific CML may overshadow SB-specific CML during concurrent sensitization (Tables IV and V, DRw3 reagent).
Serologic and structural studies provide evidence for two segregant series of B cell antigens. Two groups have recently reported isoelectric focusing studies indicating two similar but distinct species of polymorphic B cell antigens (13, 14) . Serologic studies with alloantisera (9, 10) and monoclonal antisera (11) have also suggested more than one kind of human Ia molecule. Collaborative studies are in progress to test whether the SB antigens defined functionally in this report are the same as those being defined serologically by other laboratories.
Second, what is the relationship between the proliferation-inducing antigens and the CML target antigens? The data suggest that they are identical antigens; however, the data do not exclude the possibility that they are distinct but very strongly associated. If proliferation-inducing antigens and CML antigens are distinct but linked, they might not be distinguishable in the A1,2,B7,8 donors because of the strong linkage disequilibrium of A1-B8-DRw3 and A2-B7-DRw2 haplotypes; however, studies of other donors (such as the family in Table VII and six other unrelated donors [data not shown]) demonstrate no convincing discordance. Because the data fail to demonstrate any differences, we make the working hypothesis that they are identical. Third, are the SB antigens part of a single segregant series? Evidence in this report and to be reported subsequently suggests strongly that they comprise a single series. Family studies indicate that SB markers can be identified on 29 out of 45 haplotypes tested, with no haplotype having two markers. In populations studies, 129 SB antigens have been identified on 92 donors with no donor typing for more than 2 antigens. Although the data are still too limited to be tested meaningfully for Hardy-Weinberg equilibrium, they strongly suggest these antigens are part of a single segregant series. In addition, attempts to distinguish between the SB antigens in terms of tissue distribution and their function in allogeneic responses have failed to provide any evidence that they are different.
Fourth, what is the relationship between the SB antigens defined in this report, and the HLA-DR antigens? There are four similarities between these two series of antigens. First, both are coded in the same region of HLA--centromeric to HLA-B. Second, both are preferentially expressed on B cells rather than T cells. Third, both induce strong secondary proliferative responses in mixed lymphocyte culture. Fourth, both SB and DR appear to be target antigens for CML (although in both cases it cannot be ruled out that the target antigen is distinct and closely associated).
The only functional difference that we currently recognize between the function of DR and SB is quantitative not qualitative: DR-specific CML and D/DR-induced proliferation are regularly seen in primary responses, whereas SB-specific CML and proliferation is minimal in primary responses (S. Shaw. Unpublished observations.). The quantitative rather than qualitative differences in the responses to these functionally similar antigens can be explained by the hypotheses that the amount of the SB antigen present on the B cells is substantially less than the amount of DR, or that the size of the T cell repertoire that recognizes SB antigens is smaller than the repertoire that recognizes DR antigens.
Despite the functional similarities between the DR and SB antigens, they are clearly distinct. Population studies (Table II; Table III) demonstrate that a single SB antigen segregates with different DR antigens on different haplotypes. However, the molecular relationship between these antigens remains unclear. We favor the hypothesis that DR and SB are located on distinct molecules, but further studies will be required to test the alternate possibility that DR and SB are independent determinants on the same molecule.
Fifth, what may be the role of SB antigens in responses to modified-self antigens? This report demonstrates that the SB antigens are major histocompatibility antigens not only because they are encoded by MHC genes, but also by the functional criteria that the proliferative and cytotoxic responses to the SB antigens are not restricted by HLA-DR or HLA-A, -B. The striking similarities between the SB and DR antigens suggest that these two segregant series of antigens are products of duplicated ancestral genes. We have already established that they function in qualitatively similar ways in allogeneic proliferative and cytotoxic responses. We expect that DR and SB antigens will be found to have functionally similar roles in responses to modified self antigens. Specifically, we anticipate that SB antigens will restrict clones of T cells proliferating in response to foreign antigen, as has been shown for DR antigens (37, 38) . Furthermore, SB antigens will probably restrict certain clones of cytotoxic T cells responding to foreign antigen, as we have recently suggested for DR in CML specific for the hapten trinitrophenyl (39) . We expect that in modified-self responses, as in ailogeneic responses, the SB-restricted component will be smaller than the HLA-DR-restricted component. However, in selected responses, SB may be the dominant restriction antigen. Finally, SB antigens, like DR antigens (40) , may prove to be important markers of disease risk, or even to be involved directly in the pathogenesis of certain diseases.
Summary
Five new histocompatibility antigens, designated secondary B cell or (SB) antigens, have been identified by secondary allogeneic proliferative and cytotoxic responses. The reagents used to define the SB antigens are lymphocytes primed between donors matched for all known HLA antigens. The SB antigens stimulate weak primary allogeneic proliferative responses (a mean relative response of 8%) but strong secondary proliferative responses. Strong secondary cell-mediated cytotoxicity is generated against target antigens that are indistinguishable from the SB antigens defined by proliferation. Studies by direct lysis and by cold-target inhibition indicate that these target antigens are preferentially expressed on B cells relative to T cells. The SB antigens segregate with HLA, and the gene(s) encoding the SB 1, 3, and 4 antigens maps centromeric to HLA-B. The SB antigens are major histocompatibility antigens not only because they are encoded by major histocompatibility complex (MHC) genes, but also by the functional criteria that the proliferative and cytotoxic responses to SB antigens are not restricted by HLA-DR or HLA-A, -B. Parallel studies of the SB antigens and the DR antigens indicate that there are striking functional similarities between SB and DR antigens with respect to: (a) their preferential expression on B cells, (b) their function in secondary allogeneic proliferative and cytotoxic responses, and (c) the location of their structural gene within the MHC. However, the SB antigens and the DR antigens are clearly distinct antigens, because population studies indicate that they can occur independently, and family studies indicate that specific SB antigens segregate with HLA haplotypes having different D and DR specificities. Our data are consistent with the hypotheses that the SB antigens are a new segregant series of B cell alloantigens, and that the SB gene and the DR gene derive from a duplicated ancestral gene.
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